2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - R02-R05
Treatment Considerations, Combination Therapy, Drug Development, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

527 The addition of abemaciclib to ruxolitinib in previously treated patients with myelofibrosis is safe and reverses disease progression

Jan Philipp Bewersdorf, MD, Andriy Derkach, PhD2, Amer M. Zeidan, MD3, Emily Burton4, Katherine Kan, NP5, Marissa Giuliani6, Jeetayu Biswas, MD, PhD7, Michael Mauro, MD8, Brian Chernak, MD9, Tamanna Haque, MD10, Nikolai Podoltsev Podoltsev, MD, PhD11, Prithviraj Bose, MD12, Ross L. Levine, Prof. Dr.13, Raajit K. Rampal, MD, PhD14
1 Yale University School of Medicine, New Haven, Connecticut, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Yale University School of Medicine, New Haven, Connecticut, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Yale University School of Medicine, New Haven, Connecticut, United States
12 MD Anderson Cancer Center, Houston, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background: Myelofibrosis (MF) is characterized by activating mutations in the JAK-STAT pathway. The JAK inhibitor ruxolitinib (RUX) improves disease-related symptoms and splenomegaly but has limited disease-modifying activity. Activating JAK-STAT mutations drive myeloproliferation by promoting G1/S phase cell cycle progression via increased expression of CDC25A, cyclin D, and CDK6. We and others previously demonstrated in preclinical MF models that combining JAK inhibition and cell cycle inhibition using CDK4/6 inhibitors yields greater activity than JAK inhibition alone.

Methods: We conducted a phase I dose-escalation trial (NCT05714072) to evaluate the safety of combination therapy with RUX and the CDK4/6 inhibitor abemaciclib (ABE) in patients (pts) with MF who had an inadequate response to at least 12 weeks of RUX monotherapy, defined as either persistent splenomegaly (≥450 cm³ by imaging) or MPN-SAF Total Symptom Score (TSS ≥5). Pts required platelets ≥75 × 109/L and < 10% circulating or bone marrow blasts to enroll. Using a “3+3” design, three escalating dose levels (DL) of ABE (50 mg, 100 mg, and 150 mg all BID) were combined with fixed doses of RUX 10 mg BID or 15 mg BID. Safety and determination of the recommended phase II dose (RP2D) of the combination therapy were the primary endpoints. Adverse events (AEs) were graded according to CTCAE v5.0. Dose-limiting toxicities (DLTs) were defined as grade ≥3 AEs during the first 28 days of combination therapy if related to either study drug. Secondary endpoints included spleen volume reduction by 25% (SVR25) and 35% (SVR35) at any point during the trial and absolute change in MPN-SAF TSS.

Results: As of July 2026, enrollment is complete, and 11 pts were enrolled (3 pts each at DL0 and DL1, 5 at DL2). Median age at enrollment was 66 years [range: 54-76], 8 pts had a JAK2V617F and 3 pts a CALR mutation. All pts had DIPSS intermediate/high risk disease. Baseline disease characteristics included (median [range]): spleen volume 1991cm3 [531-3587cm3], MPN-SAF TSS 33 [14-47], WBC 26.4 x 109/L [5-70 x 109/L], peripheral blood blasts 2% [0-7%], and LDH 943 U/L [202-2915 U/L]. Median time on study thus far is 13 cycles (range: 4-28) with 7 pts still on treatment at time of data cut-off. No DLTs or AE-related treatment discontinuations were observed. The only grade 3 treatment-emergent AEs were anemia (n=2) and neutropenia (n=1). All remaining AEs were grade 1/2, with diarrhea (62.5%), anemia (25%), and neutropenia (25%) being the most common. Three pts had dose reductions at DL2 outside the DLT period due to diarrhea. No dose modifications were required at DL0 or DL1. At the data cutoff, 9 out of 11 treated pts were evaluable for spleen and symptom responses. Seven out of 9 pts (78%) achieved SVR25, including 5 (56%) who achieved SVR35, with a median spleen volume reduction of 32% (range, −55.5% to +19.6%). Three out of 4 pts who achieved SVR25 and remained on therapy for > 12 cycles continued to maintain a response. Two pts entered the study with progressive splenomegaly (8cm > 19cm after 7 months on RUX, 5cm > 21cm after 17 months on RUX) and leukocytosis (8.9 x 109/L >27 x 109/L and 14.1 x 109/L > 57.6 x 109/L). After the addition of ABE, these pts achieved SVR48 and SVR38, respectively, as well as a normalization of the WBC. Another patient on treatment with RUX + placebo/pelabresib entered the study with an increase of spleen volume 1716 cm3 > 2655 cm3 and leukocytosis (12.1 x 109/L > 21.5 x 109/L) and achieved SVR25 and normalization of WBC after the addition of ABE to RUX.

Additionally, 6 out of 9 pts had TSS reduction with median change in absolute TSS of -4 (-13 - +12). Leukocytosis resolved in 7 out of 9 evaluable pts by cycle 4. Serial molecular genetic data was available on 4 pts; two patients with JAK2 mutations had VAF reductions of 30% and 24%, respectively. Two pts with CALR mutations had 10% and 0% change in VAF, respectively.

Conclusions: The combination of RUX and the CDK 4/6 inhibitor ABE among pts with advanced, previously treated MF is safe and has encouraging efficacy (78% SVR25), including reversing spleen size progression in pts on single-agent RUX. These data support the further exploration of this combination in pts with MF. DL1 has been declared the RP2D and dose expansion at this dose is ongoing.

Jan Philipp Bewersdorf, MD: No relevant conflicts of interest to declare.